Clear Harbor Asset Management, LLC Infinity Pharmaceuticals, Inc. Transaction History

Clear Harbor Asset Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 04, 2021	SELL	$1.05 - $2.77 $33,516 - $88,418	-31,920 Closed	0 $0
Q3 2020 Oct 26, 2020	SELL	$0.82 - $1.34 $164 - $268	-200 Reduced 0.62%	31,920 $37,000
Q1 2020 May 08, 2020	BUY	$0.69 - $1.52 $983 - $2,166	1,425 Added 4.64%	32,120 $27,000
Q4 2019 Jan 29, 2020	SELL	$0.88 - $1.29 $3,894 - $5,708	-4,425 Reduced 12.6%	30,695 $29,000
Q3 2019 Oct 31, 2019	SELL	$1.03 - $1.75 $33,227 - $56,455	-32,260 Reduced 47.88%	35,120 $36,000
Q2 2019 Jul 22, 2019	SELL	$1.43 - $1.87 $7,150 - $9,350	-5,000 Reduced 6.91%	67,380 $121,000
Q1 2019 Apr 19, 2019	SELL	$1.18 - $1.91 $2,950 - $4,775	-2,500 Reduced 3.34%	72,380 $136,000
Q4 2018 Feb 11, 2019	SELL	$1.01 - $2.78 $22,977 - $63,244	-22,750 Reduced 23.3%	74,880 $88,000
Q3 2018 Oct 26, 2018	BUY	$1.72 - $2.71 $3,440 - $5,420	2,000 Added 2.09%	97,630 $200,000
Q2 2018 Aug 03, 2018	BUY	$1.72 - $2.26 $18,920 - $24,859	11,000 Added 13.0%	95,630 $183,000
Q1 2018 May 01, 2018	SELL	$1.8 - $2.74 $124,506 - $189,525	-69,170 Reduced 44.97%	84,630 $178,000
Q4 2017 Jan 23, 2018	BUY	$1.22 - $3.73 $187,636 - $573,674	153,800	153,800 $312,000

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of Clear Harbor Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Clear Harbor Asset Management, LLC with notifications on news.